Aired 4 months ago 3:07
howard levin mark elfin Discussed on MedTech Talk Podcast
MedTech Talk Podcast
From the news
Aired 4 months ago 37:55
Gelfand and Levin Share Lessons from Ardians Rise and Falland Rise Again. Would They Do It Again?
Howard Levin and Mark Gelfand, the principals of Coridea, return to the podcast to detail the trials and tribulations of Ardian. Ardian is one of the bigger #medtech #startup stories over the past two decades. In 2011, Medtronic agreed to pay $800 million upfront for this company that pushed the once crazy idea of ablating renal nerves to lower hypertension. Ardian had raised $70 million from a syndicate of blue chip investors after being forged in the Foundry incubator. VCs proudly shared that the earnouts for Ardian would push that price well over $1 billion. This was a HUGE win for Medtech when it desperately needed it. Three years later came the fall. A day before JP Morganâ€™s Healthcare Meeting in 2014, Medtronic announced early disappointing of SYMPLICITY HTN-3, a third and larger trial of Ardianâ€™s renal denervation. Medtronic revised the trial, running Spryal HTN on patients who didnâ€™t take any medication for their hypertension â€“ a contrast from the Symplicity trial where patients were taking an average of five medications. In these revised trials, renal denervation is performing much better. The new results exonerated Ardianâ€™s early backers â€“ and perhaps Gelfand and Levin, specifically. This was the team, after all, that combed through medical libraries for clues about hacking the human body to beat back hypertension. The research turned up the discovery that surgeons once would treat extremely unresponsive hypertension by severing nerves near the kidney. The procedure worked, but it was dangerous. Levin and Gelfand saw ablating tissue as a safer path. And, after a lot of trudging up and down the Valley, finally found a willing partner in the team at The Foundry. Early clinical success led to a renal denervation gold rush. Nearly every VC and Strategic investor had a bet in this space. The 2014 debacle convinced many to close their programs and companies, but now Renal Denervation is back in favor. How did Howard Levin and Mark Gelfand enjoy the roller coaster ride? In this podcast, weâ€™ll talk about Ardian, TAVR, the challenges facing Medtech VCs and the poor reception many surgeons give new interventional technologies.
Aired 5 months ago 30:26
Mark Gelfand, Howard Levin Discuss Coridea, Ardian and How Theyre Innovating Medtech Innovation
Over the past decade, no other Medtech start-up has moved markets as much or as quickly as Ardian, the godfather of the renal denervation surge a decade ago. But the gold rush dried up in 2014 when Medtronic delivered disappointing clinical trial news that left many to declare â€œRenal Denervation is Dead.â€ Well, if we may borrow from Monty Python, renal denervation is not dead yet. In this two-part podcast, we talk with Mark Gelfand and Howard Levin, the principals of Coridea, who developed Ardianâ€™s approach. We'll talk with them about their path to creating Coridea, the state of innovation, and, of course, how the Ardian â€œOperaâ€ influenced them going forward.
Aired 3 months ago 116:02
Episode 97 Celebrating 30 Years of Batman
Weâ€™ve been looking forward to this episode for over a year! Nowâ€™s our chance to celebrate the man, the myth, the Bat!Â This weekâ€™s Reel Chronicles looks back at the legend that is Batman as it [...] The post Episode 97 â€“ Celebrating 30 Years of Batman appeared first on Reel Talk Inc..